Secondary Logo

Institutional members access full text with Ovid®

Dabigatran etexilate versus low-molecular weight heparin to control consumptive coagulopathy secondary to diffuse venous vascular malformations

Ardillon, Laurent; Lambert, Catherine; Eeckhoudt, Stéphane; Boon, Laurence M.; Hermans, Cedric

Blood Coagulation & Fibrinolysis: March 2016 - Volume 27 - Issue 2 - p 216–219
doi: 10.1097/MBC.0000000000000412

Diffuse venous malformations can be associated with a consumptive coagulopathy characterized by a reduction of fibrinogen level, platelet count and elevated D-dimer level. We report a case of a patient with extensive venous malformations, hemorrhagic symptoms and biological signs of intravascular coagulopathy. She was initially treated effectively with low-molecular weight heparin (LMWH) (enoxaparin 1 mg/kg, bid) and switched to low-dose dabigatran etexilate (110 mg bid) for more than 2 years. Both treatments showed a similar clinical efficacy with the absence of bleeding or thrombotic complications. Compared with LMWH, dabigatran etexilate provided a similar correction of the fibrinogen level and platelet count but was less effective to reduce the D-dimer level. Although dabigatran etexilate can be safely used to control the consumptive coagulopathy secondary to venous malformation and provides a practical alternative to LMWH, its efficacy in vivo at a low dose to reduce the D-dimer level was lower than that of LMWH.

aHaematology–Haemostasis Unit, University Hospital, Tours, France

bHaemostasis and Thrombosis Unit, Haemophilia Clinic, Division of Haematology

cHaemostasis Laboratory, Department of Biological Chemistry

dDivision of Plastic and Reconstructive Surgery, Center for Vascular Anomalies, Clinic of the Saint-Luc University Hospital, Catholic University of Leuven, Brussels, Belgium

Correspondence to Professor Cedric Hermans, MD, FRCP (Lon, Edin), PhD, Haemostasis and Thrombosis Unit, Division of Haematology, Haemophilia Clinic, St-Luc University Hospital, Avenue Hippocrate 10, 1200 Brussels, Belgium Tel: +32 2 764 17 85; fax: +32 2 764 89 59; e-mail:

Received 19 May, 2015

Revised 22 July, 2015

Accepted 4 August, 2015

Copyright © 2016 YEAR Wolters Kluwer Health, Inc. All rights reserved.